Usenamine a potentiates anti-CRC activity of sorafenib by inducing autophagy and inhibiting YAP pathway through targeting SOD2 - PubMed
3 hours ago
- #Autophagy
- #Colorectal Cancer
- #SOD2
- Usenamine A (UD32-3) enhances the anti-CRC effects of sorafenib by inducing autophagy and inhibiting the YAP pathway via targeting SOD2.
- UD32-3 increases ROS-mediated autophagy and suppresses the YAP pathway, contributing to its anti-CRC activity.
- Knockdown of SOD2 enhances UD32-3's effects by increasing ROS and autophagy while inhibiting YAP, whereas SOD2 overexpression reduces these effects.
- Combination therapy with UD32-3 and sorafenib shows synergistic anti-tumor effects by activating autophagy and inhibiting the YAP pathway.
- A YAP inhibitor further strengthens the anti-CRC activity of UD32-3 and sorafenib by suppressing SOD2 expression, indicating a feedback loop between SOD2 and YAP.
- UD32-3 has significant therapeutic potential, and its combination with sorafenib could be an effective strategy for certain CRC patients.